Velagliflozin proline is an oral sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations. In Vivo Velagliflozin (1 mg/kg; p.o.; single dose) proline increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats . Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) proline is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid-liquid mixture
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Velagliflozin proline
CAS number：1539295-26-5 molecular formula：C28H34N2O7
overview
compound introduction
Specs
| Chinese alias | 维拉格列净脯氨酸 | ||
| English alias | - | ||
| CAS number | 1539295-26-5 | molecular formula | C28H34N2O7 |
| molecular weight | 510.58 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
